ClinicalTrials.gg
Active, not recruitingNCT06125951XanaMIAUpdated Oct 21, 2026

Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease

A Phase 2/3 interventional study of Xanamem and Placebo in Dementia Moderate, Dementia, Mild and Alzheimer Disease, sponsored by Actinogen Medical. Active, not recruiting at 34 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Primary conditionAlzheimer DiseaseRegistry: DementiaReclassifiedWhy we changed it
Registry
Dementia — the first condition term the registry derived for this study.
ClinicalTrials.gg
Alzheimer Disease
Why
  1. The study's listed conditions name Alzheimer Disease, a narrower term within Dementia.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Actinogen Medical · Phase 2/3, Interventional, and Treatment

How we know

Updated Oct 13, 2026Primary completion moved1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
247
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,941 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 444 under way, 40 of them phase 3. Alzheimer Disease · United States.

Enrollment
365th of 1,610
247 · median 73
Started
2024
with 113 others
Phase 2/3
42 of 1,941
5 open now
Primary completion
2026-09
later than 73 of 443 live
Registered
1,639th of 1,941
by date

Among the 1,941 studies in Alzheimer Disease with a site in United States, this one is the 365th largest by enrollment of the 1,610 interventional ones that give a count, is one of 114 that started in 2024, is one of 42 in phase 2/3, reaches primary completion later than 73 of the 443 other live ones, and was the 1,639th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,941 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,941 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

Xanamem® is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD).

This XanaMIA Phase 2b/3 study is to investigate the safety, tolerability, and efficacy of Xanamem in in mild or moderate dementia due to AD. Trial participants will be randomized to either receive 10mg of Xanamem once daily or a placebo for 36 weeks at a 1:1 ratio in a double-blinded fashion. Participants who have completed the main trial will be eligible to participate in an open-label phase, which involves treatment with 10mg Xanamem once daily for a treatment period of up to a maximum of 108 weeks. The OLE is intended to finish when all participants have completed at least 60 weeks of treatment and a follow-up visit 4 weeks later.

03

Conditions studied

  • Dementia Moderate
  • Dementia, Mild
  • Alzheimer Disease

Browse trials for

Keywords

  • Xanamem
  • Actinogen
  • Alzheimer's Disease
  • Cortisol
  • emestedastat
04

In context

Alzheimer Disease Reclassified

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

This study's enrollment of 247 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.

Browse Alzheimer Disease studies →

Lead sponsor

Actinogen Medical is the lead sponsor of 6 studies on the registry; none are open to participants now.

Compared within Alzheimer Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dementia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 50 years or older, inclusive at the time of Screening.
  • Clinical syndrome of mild or moderate dementia, likely to be due to AD in the opinion of the Investigator, at Screening, including meeting the following criteria:

    1. Clinical Dementia Rating (CDR) global score of 0.5 to 1.0
    2. (MMSE) score of 18 to 26
    3. Magnetic resonance imaging (MRI) or computerized tomography (CT) scan within 1 year prior to randomization that excludes alternative diagnoses for dementia such as large stroke, likely vascular dementia, brain tumor, subdural hematoma, or other non-AD dementia type findings
    4. Positive plasma AD biomarker signature at Pre-screening, comprising fasting levels of a tau species protein.
  • If receiving symptomatic AD medications, the dosing regimen must have been stable for 3 months prior to Screening.
  • Has a consenting trial partner who, in the Investigator's judgment, has frequent and sufficient contact with the participant to be able to provide accurate information as to the participant's cognitive and functional abilities. The trial partner must be available to provide information to the Investigator and trial site staff about the participant and agrees to attend all trial site visits in person for scale completion. A trial partner should be available for the duration of the trial. The measure of adequate availability will be at the Investigator's discretion.
  • Participants must be able to comfortably abstain from caffeine intake for 4 hours prior to scheduled cognitive assessments.
  • Smokers are eligible if they are able to comfortably abstain from nicotine / tobacco products for 2 hours prior to scheduled cognitive assessments.
  • Must provide written to participate in the trial and be willing and able to participate for the maximum of 9 months of treatment and up to 11.5 months of site visits.

Exclusion criteria

Exclusion Criteria:

  • Use of anti-amyloid or anti-tau antibody within 6 months.
  • Diagnosis of a non-AD dementia including traumatic brain injury.
  • Diagnosis of an active major mental illness of concern in the opinion in the Investigator, including major depressive disorder, bipolar illness, or schizophrenia.
  • Participation in another clinical trial of a drug or device
  • Has a or body weight that will interfere with participation in the trial, including inadequate venous access to complete the trial assessments, to be determined at the discretion of the Investigator.
  • Previous systemic illness or infection, including test positive COVID-19, within the past 4 weeks prior to Screening.
  • Clinical diagnosis of Type I or Type II diabetes requiring insulin.
  • Exhibit physical, cognitive, or language impairments, in the opinion of the Investigator, of such severity as to adversely affect the validity of the data derived from the neuropsychological tests.
  • Trial participants with evidence of current infection with , , or .
  • Participants with a history of clinically significant drug abuse or addiction in the past 2 years
  • Evidence or history of alcohol abuse
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

06

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
247 participants (actual)

Study arms

  • Experimental
    10 mg Xanamem

    10 mg Xanamem tablet, to be administered orally once every morning with or without food

    Drug: Xanamem

  • Placebo comparator
    Placebo

    Placebo tablet, to be administered orally once every morning with or without food

    Drug: Placebo

  • Experimental
    Open label phase

    Participants enrolled in the open-label phase after the main trial will receive 10 mg Xanamem, to be administered orally once every morning with or without food

    Drug: Xanamem

Interventions

  • DrugUE2343Studies of UE2343UE2343 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Xanamem drug product is formulated as an immediate-release film-coated tablet formulation for oral administration. Each Xanamem tablet contains 10 mg Xanamem (UE2343) drug substance and excipients.

    Also known as: UE2343

  • DrugPlacebo

    Matching placebo which is identical in appearance to the test product (10 mg Xanamem once daily) except that it contains no active ingredient.

07

What researchers measure

Primary outcomes

  1. Effects of 10 mg Xanamem on integrated cognitive and functional abilities

    Change from Baseline to end of treatment (EOT) in the Clinical Dementia Ratio - Sum of Boxes (CDR-SB). The CDR-SB is calculated as an average score, with lower scores indicating improvement.

    Time frame: 36 weeks

  2. Incidence and severity of treatment-emergent adverse events (TEAEs) [safety and tolerability of Xanamem]

    Incidence and severity of TEAEs

    Time frame: 36 weeks

08

Study locations

34 sites
  • ACW Investigative Site 218
    Carlsbad, California 92011, United States
  • ACW Investigative Site 209
    Sherman Oaks, California 91403, United States
  • ACW Investigative Site 211
    Denver, Colorado 80218, United States
  • ACW Investigative Site 208
    Englewood, Colorado 80113, United States
  • ACW Investigative Site 203
    Delray Beach, Florida 33445, United States
  • ACW Investigative site 201
    Miami, Florida 33176, United States
  • ACW Investigative site 202
    New Port Richey, Florida 34652, United States
  • ACW Investigative site 204
    Orlando, Florida 32803, United States
  • ACW Investigative site 205
    The Villages, Florida 32162, United States
  • ACW Investigative Site 207
    Decatur, Georgia 30030, United States
  • ACW Investigative Site 206
    Marlton, New Jersey 08053, United States
  • ACW Investigative Site 214
    Albany, New York 12208, United States
  • ACW Investigative Site 219
    Staten Island, New York 10314, United States
  • ACW Investigative Site 210
    Dayton, Ohio 45459, United States
  • ACW Investigative Site 217
    Independence, Ohio 44131, United States
  • ACW Investigative Site 212
    Portland, Oregon 97225, United States
  • ACW Investigative Site 216
    East Providence, Rhode Island 02914, United States
  • ACW Investigative Site 220
    Austin, Texas 78757, United States
  • ACW Investigative Site 215
    Bellevue, Washington 98007, United States
  • ACW Investigative Site 106
    Darlinghurst, New South Wales, Australia
  • ACW Investigative Site 103
    Erina, New South Wales, Australia
  • ACW Investigative Site 102
    Kogarah, New South Wales, Australia
  • ACW Investigative Site 107
    Macquarie Park, New South Wales, Australia
  • ACW Investigative Site 111
    Newcastle, New South Wales, Australia
  • ACW Investigative Site 113
    Birtinya, Queensland, Australia
  • ACW Investigative Site 105
    Chermside, Queensland, Australia
  • ACW Investigative Site 114
    Bedford Park, South Australia, Australia
  • ACW Investigative Site 110
    Woodville South, South Australia, Australia
  • ACW Investigative Site 115
    Carlton, Victoria, Australia
  • ACW Investigative Site 101
    Ivanhoe, Victoria, Australia
  • ACW Investigative Site 108
    Malvern, Victoria, Australia
  • ACW Investigative Site 112
    Parkville, Victoria, Australia
  • ACW Investigative Site 104
    Nedlands, Western Australia, Australia
  • ACW Investigative Site 109
    West Perth, Western Australia, Australia
09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Sep 2026, 29 months.

Of 28 phase 2/3 interventional studies under Alzheimer Disease, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 70. This study's 29 months is below that.

Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Sep 2026, on Oct 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2023
First posted
Nov 9, 2023
StartActual
Apr 12, 2024
Primary completionActual
Sep 22, 2026was Oct 2026
CompletionEst.
Feb 2028
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • ACW Investigative Site 206 · Marlton, United States
Show 1 removed
  • ACW Investigative Site 206 · Toms River, United States
Oct 13, 2026
Primary completion
Oct 2026→Sep 22, 2026 (actual)
Oct 5, 2026
Show all 2 updates
  1. Oct 13, 2026
    1 site added, 1 site removed
    Show site
    • ACW Investigative Site 206 · Marlton, United States
    Show 1 removed
    • ACW Investigative Site 206 · Toms River, United States
  2. Oct 5, 2026
    Primary completion Oct 2026→Sep 22, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06125951
Lead sponsor
Actinogen Medical
Responsible party
Sponsor
First posted
Nov 9, 2023
Start date
Apr 12, 2024
Primary completion
Sep 22, 2026
Completion
Feb 2028 (estimated)
Last update
Oct 21, 2026

Study contacts

Global Program Lead
study director · Actinogen Medical Ltd

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: UE2343

Start the discussion